Cargando…
Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain
The oncolytic mutant vesicular stomatitis virus VSVΔ51 achieves robust efficacy in multiple extracranial tumor models. Yet for malignancies of the brain, direct intratumoral infusion of VSVΔ51 causes lethal virus-induced neuropathology. Here, we have developed a novel therapeutic regime that uses pe...
Autores principales: | Balathasan, Lukxmi, Tang, Vera A., Yadollahi, Beta, Brun, Jan, Labelle, Melanie, Lefebvre, Charles, Swift, Stephanie L., Stojdl, David F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645178/ https://www.ncbi.nlm.nih.gov/pubmed/29062886 http://dx.doi.org/10.1016/j.omto.2017.09.004 |
Ejemplares similares
-
Functional genomic screening to enhance oncolytic virotherapy
por: Mahoney, D J, et al.
Publicado: (2013) -
The Role of the Innate Immune System in Oncolytic Virotherapy
por: Phan, Tuan Anh, et al.
Publicado: (2017) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012) -
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
por: Roy, D. G., et al.
Publicado: (2021) -
Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)